Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma
NCT07359846 is registered in ClinicalTrials.gov with Generate Biomedicines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma
- Lead sponsor
- Generate Biomedicines
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 20, 2026
- Completion date
- January 31, 2029
- Enrollment
- 786 (estimated)
- Sites
- 132
Conditions
As the registry lists them; a condition with its own page is linked.
severe asthma